The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...
INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) revealed long-term study results indicating that over 80% of adults and adolescents with moderate-to-severe atopic dermatitis... ByInvesting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback